SULFASALAZINE

Important: Therapy notes

  • Regular monitoring is required, refer to DMARD monitoring.
  • Advise patients receiving sulfasalazine to report any unexplained bleeding, bruising, purpura, sore throat, fever or malaise that occurs during treatment.
  • Perform a blood count and stop the drug if there is suspicion of a blood dyscrasia.
  • Note that enteric-coated sulfasalazine tablets are preferred in rheumatoid arthritis patients because they cause less nausea and fewer gastro-intestinal side-effects than standard tablets.
  • For NHS Highland Rheumatology Department GP and Patient information click here (NHSH intranet access required)

Important: Formulation and dosage details

Formulation:

Enteric coated tablets 500mg (s)

Important: Formulation and dosage details

Formulation:

Suspension 250mg/5mL (s)

Editorial Information

Document Id: F277